Abdul Mannan Inside the Diagnostic Maze of Atypical CML
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”It’s rare. It’s aggressive. It mimics other blood cancers.
No Philadelphia chromosome. No targeted therapy. Just tough decisions.
Diagnosis needs sharp eyes. Dysplastic cells. High white counts. Molecular clues.
SETBP1 and ASXL1 mutations tell the story.
CSF3R points elsewhere.
Median survival? 14-30 months without transplant.
But here’s hope: Early recognition matters. Molecular testing guides us. Transplant can cure selected patients.
Every rare diagnosis teaches us something profound about blood biology.
As haematologists, we don’t just treat diseases. We solve puzzles that save lives.
What rare condition taught you the most?”
Keep up with Hemostasis Today.
-
Jul 9, 2026, 12:41Thomas Palmer-Dench: Hexokinase Controls Platelet Activation and Hemostasis
-
Jul 9, 2026, 12:19Paschalis Evangelidis: Join Our Special Issue on Thrombosis and Vascular Disorders
-
Jul 9, 2026, 12:16Fernanda Betti Solano: Could Iron Deficiency Be Affecting Your Sleep?
-
Jul 9, 2026, 12:08Andreas Calatzis: What is the Rationale for Collagen-Induced Platelet Aggregation Testing?
-
Jul 9, 2026, 11:54Deepak Pradhan։ Can Withaferin-A Help Combat Drug-Resistant Malaria?
-
Jul 9, 2026, 11:26Peter Zhang: Is Canada Ready for the Gene Therapy Era?
-
Jul 9, 2026, 09:35Pradeebha Muthukumar: Do You Know the Signs of Anemia?
-
Jul 9, 2026, 09:24Maryam Majid: Machine Learning for Anemia Risk Prediction
-
Jul 9, 2026, 08:46Jordan Agay: Folate Deficiency in Patients Receiving PARP Inhibitors